Compare Bilcare with Similar Stocks
Dashboard
High Debt company with Weak Long Term Fundamental Strength
- Poor long term growth as Net Sales has grown by an annual rate of 5.46% and Operating profit at 5.58% over the last 5 years
- High Debt Company with a Debt to Equity ratio (avg) at 3.95 times
- The company has reported losses. Due to this company has reported negative ROE
Flat results in Dec 25
Risky - Negative Operating Profits
Below par performance in long term as well as near term
Stock DNA
Healthcare Services
INR 130 Cr (Micro Cap)
NA (Loss Making)
14
0.00%
1.38
-3.67%
0.28
Total Returns (Price + Dividend) 
Latest dividend: 2 per share ex-dividend date: Sep-20-2012
Risk Adjusted Returns v/s 
Returns Beta
News

Bilcare Ltd is Rated Strong Sell
Bilcare Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 18 Nov 2025. However, the analysis and financial metrics discussed here reflect the company’s current position as of 26 March 2026, providing investors with an up-to-date view of its fundamentals, valuation, financial trends, and technical outlook.
Read full news article
Markets Rally, But Bilcare Ltd Sinks to 52-Week Low in Stock-Specific Sell-Off
While the broader market showed signs of recovery, Bilcare Ltd slipped to a fresh 52-week low of Rs 51.75 on 24 Mar 2026, extending a challenging period for the healthcare services company amid persistent headwinds.
Read full news article
Markets Rally, But Bilcare Ltd Sinks to 52-Week Low in Stock-Specific Sell-Off
While the broader market has been attempting to stabilise, Bilcare Ltd has continued its downward trajectory, hitting a fresh 52-week low of Rs 52.11 on 23 Mar 2026. This decline contrasts sharply with the recent sector and market movements, underscoring company-specific pressures that have weighed heavily on the stock.
Read full news article Announcements 
Announcement under Regulation 30 (LODR)-Newspaper Publication
14-Feb-2026 | Source : BSENewspaper publication of Unaudited Financial Results (Standalone and Consolidated) for the Quarter and Nine Months ended 31st December 2025.
Unaudited Financials Result (Standalone And Consolidated) For The Quarter And Nine Months Ended 31.12.2025 Along With Limited Review Report.
12-Feb-2026 | Source : BSEBilcare Limited has informed the Exchange about the approval of Unaudited Financial Results (Standalone and Consolidated) for the period ended 31.12.2025 along with Limited Review Report.
Redemption Of Preference Shares
12-Feb-2026 | Source : BSEBilcare Limited has informed the Exchange about the Redemption of Preference Shares held by the Company in Caprihans India Limited.
Corporate Actions 
No Upcoming Board Meetings
Bilcare Ltd has declared 20% dividend, ex-date: 20 Sep 12
No Splits history available
No Bonus history available
No Rights history available
Quality key factors 
Valuation key factors
Technicals key factors
Shareholding Snapshot : Dec 2025
Shareholding Compare (%holding) 
Non Institution
1.3868
Held by 0 Schemes
Held by 1 FIIs (0.04%)
Mohan Harakchand Bhandari (24.87%)
Monument Pte Limited (16.44%)
45.45%
Quarterly Results Snapshot (Consolidated) - Dec'25 - QoQ
QoQ Growth in quarter ended Dec 2025 is 1.75% vs -4.38% in Sep 2025
QoQ Growth in quarter ended Dec 2025 is 51.86% vs -225.26% in Sep 2025
Half Yearly Results Snapshot (Consolidated) - Sep'25
Growth in half year ended Sep 2025 is -7.91% vs 6.37% in Sep 2024
Growth in half year ended Sep 2025 is 27.92% vs -44.74% in Sep 2024
Nine Monthly Results Snapshot (Consolidated) - Dec'25
YoY Growth in nine months ended Dec 2025 is -8.10% vs 8.57% in Dec 2024
YoY Growth in nine months ended Dec 2025 is 25.25% vs -32.41% in Dec 2024
Annual Results Snapshot (Consolidated) - Mar'25
YoY Growth in year ended Mar 2025 is 5.47% vs -23.88% in Mar 2024
YoY Growth in year ended Mar 2025 is 13.39% vs -320.80% in Mar 2024






